INTS — INTENSITY THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1567264 ·
Last close
$4.15
Market Cap
$11.22M
52W High
$5.35
52W Low
$3.51
ADV30
54,123
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,526,000 | -2,434,000 | 12,291,000 | 10,245,000 | 2,312,000 |
| Dec 2025 | 0 | — | -3,140,000 | -3,051,000 | 14,101,000 | 11,921,000 | 2,225,000 |
| Sep 2025 | 0 | — | -2,733,000 | -2,671,000 | 9,585,000 | 7,067,000 | 2,363,000 |
| Jun 2025 | 0 | — | -2,705,000 | -2,537,000 | 4,443,000 | 2,216,000 | 2,259,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,233,000
Investing CF
$0
Financing CF
$18,564,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,389,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-11,972,000
Pretax Income TTM
$-11,606,000
Interest Exp TTM
$0
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,972,000 | -11,606,000 | 14,101,000 | 2,225,000 | — | -9,233,000 |
| Dec 2024 | 0 | -16,585,000 | -16,268,000 | 4,783,000 | 1,865,000 | — | -15,220,000 |
| Dec 2023 | 0 | -8,319,000 | -10,538,000 | 17,295,000 | 4,133,000 | — | -7,205,000 |
| Dec 2022 | 0 | -7,550,000 | -7,582,000 | 1,757,000 | 16,855,000 | — | -5,477,000 |
TTM Snapshot
Revenues TTM
$196,000
NetIncome TTM
$-5,842,000
OpCashFlow TTM
$0
Assets (Latest)
$4,783,000
Forward EPS
$-2.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNTI | Senti Biosciences Holdings, Inc. | $10.62M | $0.34 | — |
| BCDA | BioCardia, Inc. | $12.21M | $0.82 | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.93M | $0.90 | — |
| INAB | IN8BIO, INC. | $9.93M | $1.03 | — |
| CUBT | Curative Biotechnology Inc | $9.90M | $1.29 | — |
News headlines (Yahoo Finance, 1h cache)
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
2026-07-15 14:31 · Yahoo
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
2026-07-15 11:45 · Yahoo
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
2026-07-01 12:00 · Yahoo
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
2026-05-27 16:00 · Yahoo
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
2026-05-14 12:00 · Yahoo
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 20:06 · Yahoo
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-05-01 13:55 · Yahoo
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
2026-04-16 16:00 · Yahoo
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
2026-04-15 13:15 · Yahoo
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
2026-03-27 20:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.